Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cell on the development of peritoneal metastasis

被引:56
作者
Sako, A [1 ]
Kitayama, J [1 ]
Yamaguchi, H [1 ]
Kaisaki, S [1 ]
Suzuki, H [1 ]
Fukatsu, K [1 ]
Fujii, S [1 ]
Nagawa, H [1 ]
机构
[1] Univ Tokyo, Dept Surg Oncol, Div Surg Oncol, Bunkyo Ku, Tokyo 1138655, Japan
关键词
mesothelial cell; peritoneal metastasis; VEGF; FGF-2;
D O I
10.1016/S0022-4804(03)00307-X
中图分类号
R61 [外科手术学];
学科分类号
摘要
Although peritoneal metastasis is an important factor determining the prognosis of patients with gastrointestinal cancer, the mechanisms have not yet been clearly defined. Human peritoneal mesothelial cells (HPMC) are the first line against disseminated tumor cells. Recent reports have shown that mesothelial cells are capable of secreting various cytokines and growth factors. In this study, we isolated human mesothelial cells from surgically resected omental tissue and examined the production and interaction of two major angiogenic factors, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2). Quiescent HPMC produced a considerable amount of VEGF at almost the same level as tumor cells. Interestingly, addition of FGF-2 to the culture significantly increased the mRNA synthesis and protein secretion of VEGF in a dose-dependent manner, as determined by Northern blot and ELISA. The addition of 0.5 ng/mL FGF-2 was enough to stimulate VEGF production, and the effect reached a plateau at 5 ng/mL. Reverse-transcribed polymerase chain reaction (RT-PCR) method clarified that the HPMC-derived VEGF consisted mostly of VEGF(121) and VEGF(165), which are both predominantly soluble forms. These data suggest that HPMC contribute to the development of metastases and the accumulation of malignant ascites due to the production of VEGF, especially in cancers that do not express enough amount of VEGF. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 49 条
[21]  
Kraft A, 1999, CANCER-AM CANCER SOC, V85, P178
[22]   Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer [J].
Landriscina, M ;
Cassano, A ;
Ratto, C ;
Longo, R ;
Ippoliti, M ;
Palazzatti, B ;
Crucitti, F ;
Barone, C .
BRITISH JOURNAL OF CANCER, 1998, 78 (06) :765-770
[23]  
LANFRANCONE L, 1992, BLOOD, V80, P2835
[24]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A SECRETED ANGIOGENIC MITOGEN [J].
LEUNG, DW ;
CACHIANES, G ;
KUANG, WJ ;
GOEDDEL, DV ;
FERRARA, N .
SCIENCE, 1989, 246 (4935) :1306-1309
[25]   INDUCTION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR GENE-EXPRESSION BY INTERLEUKIN-1-BETA IN RAT AORTIC SMOOTH-MUSCLE CELLS [J].
LI, J ;
PERRELLA, MA ;
TSAI, JC ;
YET, SF ;
HSIEH, CM ;
YOSHIZUMI, M ;
PATTERSON, C ;
ENDEGE, WO ;
ZHOU, F ;
LEE, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (01) :308-312
[26]   Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants [J].
Majima, M ;
Hayashi, I ;
Muramatsu, M ;
Katada, J ;
Yamashina, S ;
Katori, M .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (03) :641-649
[27]   Role of vascular endothelial growth factor in ovarian cancer -: Inhibition of ascites formation by immunoneutralization [J].
Mesiano, S ;
Ferrara, N ;
Jaffe, RB .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (04) :1249-1256
[28]   Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes [J].
Mori, A ;
Arii, S ;
Furutani, M ;
Mizumoto, M ;
Uchida, S ;
Furuyama, H ;
Kondo, Y ;
Gorrin-Rivas, MJ ;
Furumoto, K ;
Kaneda, Y ;
Imamura, M .
GENE THERAPY, 2000, 7 (12) :1027-1033
[29]  
Mutsaers SE, 1997, EUR J CELL BIOL, V72, P24
[30]  
Nakashio T, 1997, INT J CANCER, V70, P612, DOI 10.1002/(SICI)1097-0215(19970304)70:5<612::AID-IJC20>3.3.CO